Plaque Psoriasis: Causes, Triggers & Why Conventional Treatments Are Failing in 2026

Formulated in Spain since 1989  ·  Plant-Based EU-Regulated Formulas  ·  Certified Treatment Centers in 14 U.S. States

Kapyderm USA  ·  Skin Conditions  ·  Clinical Guide — July 2026

Plaque Psoriasis: Causes, Triggers
& the 2026 Treatment Landscape

More than 8 million Americans live with psoriasis. Most manage it with topical steroids, coal tar, or biologics — each with real benefits and real trade-offs. This is the honest picture: what drives the condition, what triggers flares, what each treatment actually offers, and where gentle daily skin care fits alongside medical care.

KU

Kapyderm USA — Clinical Education Team
Published July 9, 2026  ·  Last reviewed August 2026  ·  22 min read

Home › Blog › Plaque Psoriasis — Complete 2026 Clinical Guide

Please read first

Psoriasis is a chronic autoimmune disease, and this article is educational information, not medical advice. Kapyderm products are cosmetic skin care formulas. They are not drugs, they are not a treatment or cure for psoriasis, and nothing here replaces care from a dermatologist or physician. Never stop a prescribed medication — including a topical steroid — without talking to the doctor who prescribed it. Pustular and erythrodermic psoriasis can be medical emergencies; seek immediate care for a sudden widespread eruption. Individual results vary.

Quick answer

Plaque psoriasis is a chronic autoimmune inflammatory disease driven by dysregulation of the IL-23/Th17 immune axis, which accelerates skin cell turnover so cells build up faster than they shed — forming thick, scaly plaques most often on the elbows, knees, scalp and lower back. It affects more than 8 million Americans and an estimated 125 million people worldwide, and accounts for roughly 80–90% of all psoriasis cases.[2] The conventional treatment path — topical steroids, coal tar, phototherapy, systemics and biologics — is genuinely effective and carries genuine trade-offs, which this guide sets out plainly. Gentle, steroid-free daily skin care has a supporting role in comfort and barrier care alongside that treatment. It is not a replacement for it.

In this article

1. What plaque psoriasis actually is — the immune mechanism
2. Who gets psoriasis — prevalence and risk factors
3. Types of psoriasis — identification guide
4. Triggers — what causes flares
5. Where conventional treatment falls short
6. Topical steroid withdrawal — what is and isn't established
7. The gut-skin axis — what the research does and doesn't show
8. Psoriasis on skin of color
9. Treatment landscape — honest comparison
10. The Dermotricology plant-based routine
11. Frequently asked questions

What Plaque Psoriasis Actually Is — The Immune Mechanism

Psoriasis is not a skin problem with an immune component. It is an immune disease that shows itself on the skin. That distinction shapes how it is treated — and why treating only the surface gives temporary results.

In healthy skin, cell turnover runs roughly a month — new cells form in the basal layer, migrate to the surface and shed in an orderly process. In plaque psoriasis, an overactive immune cascade driven by the IL-23/Th17 pathway accelerates that cycle dramatically. New cells reach the surface faster than they shed, forming raised, scaly plaques. The same inflammation causes the redness, heat and itch — and extends systemically, which is why psoriasis is associated with psoriatic arthritis, cardiovascular disease and metabolic syndrome.[1]

The IL-23/Th17 axis — why it matters for treatment

IL-23 activates Th17 cells, which release IL-17 — a cytokine that drives keratinocyte hyperproliferation and chronic skin inflammation. The most effective pharmaceutical interventions available today — biologics such as secukinumab, ixekizumab and risankizumab — work by blocking IL-17 or IL-23 specifically.[1] That precision is exactly why they work well. It is also worth being clear about what botanical skin care does not do: no cosmetic formula blocks IL-17 or IL-23, and none of the products described later in this article act on this pathway. They work on the skin surface — comfort, scale, barrier — which is a different and more modest job.

---

Who Gets Psoriasis — Prevalence and Risk Factors

8M+ Americans living with psoriasis per the National Psoriasis Foundation, and an estimated 125 million worldwide. NPF's own prevalence page cites 3.0% of adults 20+, or more than 7.5 million adults[2]

80–90% of psoriasis cases are plaque psoriasis — making it by far the most common form of the disease[2]

30% of people with psoriasis develop psoriatic arthritis, per NPF — other sources put the range at 10–30%. Joint symptoms are a reason to see a physician, not to change a skin routine[2]

Psoriasis often first appears between the ages of 15 and 35, though it can develop at any age. A genetic component is established, with HLA-C*06:02 showing the strongest association, particularly for early-onset disease.[1] Genetics alone don't trigger it — environmental exposures, immune dysregulation and stress responses all play a part.

A correction worth making

An earlier version of this article said psoriasis affects all skin tones "equally in prevalence." That is not what the data shows. The National Psoriasis Foundation reports prevalence of 3.6% in Whites, 2.5% in Asians, 1.9% in Hispanics and 1.5% in Blacks — while noting these figures may themselves reflect health disparities, including underdiagnosis and lower rates of dermatologic care among minoritized groups.[2] The honest version is more useful than the tidy one: reported prevalence differs, and part of that difference is very likely a measurement problem rather than a biological one.

---

Types of Psoriasis — Identification Guide

Plaque psoriasis accounts for most cases, but knowing the full spectrum helps in recognizing when something is psoriasis rather than another skin condition. None of the descriptions below are a substitute for a diagnosis — only a clinician can make one.

Most Common — 80–90%

Plaque Psoriasis (Psoriasis Vulgaris)

Raised, inflamed, scaly patches — typically on the elbows, knees, lower back and scalp. Plaques are red or pink with silvery scales on lighter skin; darker, thicker purple or brown patches on skin of color. Can be localized or widespread.

Scalp

Scalp Psoriasis

Present in a large share of psoriasis patients — flaking, scaling and inflammation on or extending beyond the hairline. Often co-presents with body plaque psoriasis. Needs different formats than body care — see our dedicated scalp psoriasis guide.

Inverse

Inverse (Flexural) Psoriasis

Smooth, shiny, non-scaly plaques in skin folds — armpits, groin, under the breasts, genital area. Lacks the typical scale because friction and moisture prevent buildup. Often mistaken for a fungal infection. Skin here absorbs topicals more readily, which matters for steroid use.

Guttate

Guttate Psoriasis

Small, drop-shaped lesions appearing suddenly across the trunk and limbs — often following a streptococcal throat infection, particularly in children and young adults. May resolve on its own or develop into chronic plaque psoriasis.

Pustular — urgent

Pustular Psoriasis

Pus-filled blisters surrounded by red skin — not an infection, but requires medical evaluation. Localized forms appear on palms and soles. Generalized pustular psoriasis is rare and can be life-threatening. Any sudden widespread pustular eruption needs immediate medical attention.

Erythrodermic — emergency

Erythrodermic Psoriasis

A severe, potentially life-threatening form covering most of the body with widespread redness, scaling and shedding. A medical emergency requiring immediate care. Often triggered by abrupt medication discontinuation or infection — one more reason never to stop treatment without medical guidance.

---

Triggers — What Causes Psoriasis Flares

Psoriasis is not continuously active — it flares when triggers activate the immune cascade against a background of genetic susceptibility. Identifying personal triggers is one of the more useful things a person can do, and it works alongside medical treatment rather than instead of it.

✦

Psychological stress — the most consistently reported trigger. Stress activates the HPA axis and drives cortisol elevation, which amplifies the inflammatory cascade behind plaque formation. The relationship runs both ways: psoriasis is stressful, and stress worsens psoriasis.

✦

Medications — beta-blockers, lithium, antimalarials and NSAIDs are documented psoriasis triggers.[4] If you started a new medication and flared within weeks, raise it with your prescribing physician. Do not stop a prescribed medication on your own.

✦

Skin injuries — the Koebner phenomenon — cuts, scrapes, sunburn, insect bites, surgical incisions and tattoos can trigger new plaques at the site of injury. It is one of the best reasons to protect psoriatic skin from physical trauma and to be gentle with it.

✦

Infections — especially streptococcal — strep throat is a well-documented trigger, particularly for guttate psoriasis in children and young adults. Any systemic infection that activates the immune system can precipitate a flare.

✦

Alcohol and smoking — both are risk factors for psoriasis development and flare severity. Smoking is particularly associated with palmoplantar pustular psoriasis and is among the strongest modifiable risk factors.

✦

Weight and metabolic factors — obesity is a documented exacerbating factor; adipose tissue produces pro-inflammatory cytokines. Anti-inflammatory dietary patterns are associated with reduced flare frequency, though diet is a supporting factor rather than a treatment.

✦

Weather and environment — cold, dry conditions worsen barrier function and reduce UV exposure, and psoriasis-related search volume rises in late winter and early spring — an indirect signal, not a clinical measurement.[5]

---

Where Conventional Treatment Falls Short

The 2026 psoriasis landscape is more advanced than it has ever been. Multiple biologics are approved, IL-17 and IL-23 inhibitors achieve high clearance rates in trials, and steroid-free topical options now exist. For people who can access these treatments and tolerate them, this is real progress, and this article is not here to talk anyone out of them. But there is a gap between trial results and long-term real-world management, and it is worth naming.

Topical corticosteroids — effective, and hard to use forever

Topical steroids remain first-line for mild-to-moderate psoriasis globally, and they work. The difficulties come with the long-term use a chronic condition invites. Tachyphylaxis — a diminished response with repeated use — is documented,[4] and long-term use is associated with skin atrophy, telangiectasia, striae, and in rare cases enough systemic absorption to cause Cushing-like effects.[6] None of this means steroids are bad medicine — it means they need medical supervision over the long run.

Coal tar — old, useful, and unpopular with patients

Coal tar is one of the oldest psoriasis treatments in use. It reduces scaling and slows cell turnover. It also stains, smells strongly, causes irritation and photosensitivity, and contains polycyclic aromatic hydrocarbons — a long-standing safety discussion in the literature. The clinical consensus is that therapeutic coal tar at regulated concentrations is acceptable for its intended use; the practical problem is that people struggle to keep using it, which is a compliance issue rather than a safety verdict.

Biologics — highly effective, not universally accessible

For moderate-to-severe psoriasis, biologics targeting IL-17 and IL-23 are transformative. The barriers are cost, injection or infusion schedules, monitoring requirements, and warnings around infection risk. Published estimates of annual cost commonly run into the tens of thousands of dollars before insurance, and actual out-of-pocket cost varies enormously by coverage — so treat any single figure with caution.[3] Patient hesitancy about biologics is itself documented in the clinical literature.[7]

What we removed from this section

An earlier version carried a quotation about the industry "embracing clinical botanical solutions" that had no source attached to it, and a claim about a National Psoriasis Foundation recommendation that we could not verify at NPF. Both are gone. If we can't point to who said something, it shouldn't be in quotation marks on a page about a serious disease.

---

Topical Steroid Withdrawal — What Is and Isn't Established 2026

Topical Steroid Withdrawal (TSW) describes a group of adverse effects reported after stopping prolonged use of medium- to high-potency topical corticosteroids: burning pain, marked redness, swelling and widespread skin peeling.[8]

Here is the honest state of it, because this topic attracts a great deal of overstatement in both directions. It is real enough that a national medicines regulator acted on it: the UK's MHRA introduced new labelling on topical steroids in 2024 and reminded clinicians that reactions have been reported following long-term use — generally six months or more — of moderate or stronger potency steroids.[9] At the same time, the MHRA noted there has been little new information in the scientific literature and no accepted clinical definition. A January 2026 case series and narrative review describes TSW as an underrecognized and at times controversial diagnosis without standardized diagnostic criteria.[10]

One scope point that matters and is usually left out: most published TSW cases involve eczema, not psoriasis, and the MHRA's own advice singles out eczema treatment. That doesn't mean psoriasis patients are unaffected — the chronic nature of psoriasis does create pressure toward long-term steroid use — but the evidence base sits mostly elsewhere.

The most important safety line on this page

If you have been using topical steroids long-term, do not stop them abruptly. Rebound reactions after sudden cessation are exactly what the regulatory warnings describe, and abrupt discontinuation is also a documented trigger for erythrodermic psoriasis. Any change to a prescribed steroid should be planned with the doctor who prescribed it. A cosmetic skin care routine is not a taper plan and cannot substitute for one.

---

The Gut-Skin Axis — What the Research Does and Doesn't Show

The connection between gut health and psoriasis is one of the more active research areas in dermatology, and it is also one of the most oversold in marketing. Both things are true, so here is the line between them.

What the research reports: people with psoriasis tend to show reduced gut microbial diversity and lower levels of short-chain-fatty-acid-producing bacteria such as Faecalibacterium and Akkermansia compared with controls.[11] Separate work has examined intestinal barrier markers and their relationship to psoriasis severity.[12] This is a genuine and interesting line of investigation.

What it does not show: that any particular supplement changes the course of psoriasis. Association is not causation — reduced microbial diversity may be a consequence of systemic inflammation rather than a driver of it, and that question is not settled. No study has tested a Kapyderm supplement in psoriasis.

Why we say this plainly

It would be easy to use the gut-skin research as a reason to sell supplements harder, and plenty of brands do. We would rather be accurate: the Kapyderm supplements in this range are food supplements, not treatments for psoriasis, and the gut research is a reason to find the topic interesting, not evidence that a capsule will clear plaques. If you want to act on this area, the conversation is with your physician — particularly about diet, weight and alcohol, which have the most support of anything discussed here.

---

Psoriasis on Skin of Color

How psoriasis presents, gets diagnosed and gets treated differs meaningfully for people with darker skin, and the dermatological literature has historically underserved this population.

How it looks different: on darker skin, plaques often appear purple, grayish or dark brown rather than the classic red or pink of textbook descriptions, and scaling can look ashy. The contrast between affected and unaffected skin differs, which makes standard severity scoring less accurate. These differences contribute to misdiagnosis and delayed treatment — and NPF notes explicitly that psoriasis is likely underdiagnosed among Black patients and others with skin of color because of these presentation differences.[2]

Post-inflammatory hyperpigmentation (PIH): after plaques clear, dark marks can remain for months. PIH is more pronounced and more persistent on melanin-rich skin, which means the visible impact of psoriasis continues after the active inflammation has settled.

The practical point

Topical steroids can cause localized hypopigmentation, which is more noticeable on melanin-rich skin, and this is a legitimate thing to raise with a dermatologist when discussing treatment options. It is not a reason to avoid effective treatment — it is a reason to have the conversation. The single most useful step is being seen by a clinician who regularly treats your skin tone; asking directly how often they do is a fair question.

---

The 2026 Treatment Landscape — Honest Assessment

Option	Mechanism	Evidence	Real-World Limitations
Topical Corticosteroids	Suppress local inflammation and cell proliferation	Effective short-term — first-line globally	Tachyphylaxis; skin atrophy; systemic absorption in rare cases; rebound risk on abrupt discontinuation
Coal Tar	Slows cell turnover; anti-inflammatory	Long history of use; modest efficacy for scaling	Staining; odor; irritation; photosensitivity; poor long-term compliance
Vitamin D Analogues (calcipotriol)	Slow skin cell growth; reduce inflammation	Good evidence; suitable for longer-term topical use; often combined with a steroid	Skin irritation; limits on facial use and treated surface area; slower onset
Roflumilast (Zoryve) — topical PDE-4 inhibitor	PDE-4 inhibition; steroid-free anti-inflammatory	FDA-approved and steroid-free; once daily; strong trial evidence	Prescription only; cost and access; long-term data still accumulating
UV Phototherapy (UVB/PUVA)	Slows skin cell turnover; reduces inflammation	Strong evidence for moderate-severe disease; steroid-free	Multiple clinic visits weekly for months; cumulative UV exposure; limited accessibility
Methotrexate (oral/injection)	Immunosuppressant — reduces cell proliferation	Decades of evidence; widely accessible	Liver toxicity; pulmonary risk; regular bloodwork; teratogenic — not safe in pregnancy
Biologics (IL-17/IL-23 inhibitors)	Target specific immune cytokines — the most precise intervention available	Highest clearance rates available; transformative for severe disease	High cost before insurance; injection or infusion; infection risk warnings; access barriers
Kapyderm body skin care routine	Cosmetic skin care: keratolytic support for surface scale, gentle cleansing, botanical soothing and emollient barrier support	No controlled trial evidence in psoriasis. Cosmetic daily care intended alongside medical treatment, not instead of it	Not a drug · not a treatment for psoriasis · no medical claim · patch test before use

---

The Dermotricology Plant-Based Routine for Body Skin

What follows is a cosmetic skin care routine, not a treatment for psoriasis. Its aims are ordinary and worth stating: soften and lift surface scale so the skin can be cleansed gently, keep the barrier comfortable, and reduce the dryness and tightness that make plaques feel worse. People with psoriasis often use a routine like this alongside what their dermatologist has prescribed. Tell your dermatologist what you are using, patch test first, and never apply anything to broken or weeping skin.

1

Normalizing Base Cleanser Topical · Morning & Evening A gentle botanical cleanser for affected skin. Cleansing without stripping matters more than most people expect — harsh washing is itself an irritant, and skin injury is on the trigger list above. Suitable for multi-zone use including elbows, knees, lower back and trunk.

2

KS115 Topical · Applied to affected areas · adult use only A salicylic acid-based keratolytic formula that helps soften and lift surface scale buildup so the rest of the routine can reach the skin. It also contains willow bark, birch bark, cade wood oil and sulfur. Because cade oil is a potent traditional active, KS115 is for adult use only and is not for use on children's skin. Used as directed rather than continuously.

3

K1 Topical · Applied to affected areas A botanical oil blend — wheat germ, sunflower and rosehip oils with rosemary, fenugreek and lemon peel oil — balanced for skin that feels dry, tight or depleted. Its role here is comfort and surface condition on dry, scaling skin. It is a conditioning oil, not an anti-inflammatory medicine.

4

Special K Cream Topical · Applied to affected zones An emollient cream that helps the skin hold moisture and seals in the preceding layers. Keeping a compromised barrier comfortable is a recognized part of general skin care in dry, scaling conditions, and emollients are routinely recommended alongside medical treatment. Suitable for all skin tones; contains no steroid, so it does not carry steroid-related pigmentation or thinning concerns.

5

Fungi-Activ Topical · Where indicated A purifying botanical formula used where the skin surface would benefit from it. Note: this is a cosmetic formula, not an antifungal or antibacterial medicine, and it does not treat any infection. If an infection is suspected — increasing pain, warmth, spreading redness, weeping or crusting — that needs a physician, not a cosmetic product. Contains Methyl Nicotinate and so produces a warming response.

6

Depure Supplement Internal · 2 caps morning + 2 caps afternoon A botanical food supplement: green nettle, with dandelion, boldo, fumitory and peppermint. Taken as general nutritional support alongside the topical routine — not as a treatment for psoriasis.

7

Revital Supplement Internal · Nightly A multivitamin and mineral complex including biotin and vitamins B5, B6, C and E, taken nightly as general nutritional support.

About the supplements

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Food supplements do not replace a varied diet or prescribed medication. If you take any medication for psoriasis — particularly methotrexate, an immunosuppressant or a biologic — tell your prescribing physician about every supplement before you start one.

If you are currently using topical steroids

Do not stop them to start a cosmetic routine. Rebound flares after abrupt discontinuation are well documented, and abrupt cessation is a recognized trigger for erythrodermic psoriasis. Any change to a prescribed steroid belongs with the doctor who prescribed it, and a gentle skin care routine can run alongside prescribed treatment in the meantime.

---

Frequently Asked Questions

What causes plaque psoriasis?

Plaque psoriasis is driven by dysregulation of the IL-23/Th17 immune axis, which accelerates skin cell turnover so that cells accumulate faster than they shed, forming plaques. Genetic susceptibility (HLA-C*06:02 has the strongest association) creates the predisposition, and environmental triggers including stress, infections, certain medications and skin injury activate the immune cascade. Gut microbiome research is an active area, though the evidence there is still developing.

Why do steroid creams stop working for psoriasis?

Tachyphylaxis — a diminished response after repeated use — is a documented effect of topical corticosteroids. Long-term use is also associated with skin atrophy, telangiectasia and, rarely, systemic absorption. When steroids are stopped after prolonged use, rebound flares can occur. This is a conversation to have with your prescribing doctor rather than a reason to stop a prescribed medicine on your own.

What is topical steroid withdrawal (TSW) and does it affect psoriasis patients?

TSW describes a group of adverse effects reported after stopping prolonged use of medium- to high-potency topical corticosteroids — burning pain, redness, swelling and widespread skin peeling. The UK medicines regulator, the MHRA, added labelling about it in 2024, noting reactions generally follow six months or more of use. It remains an underrecognized and at times contested diagnosis without standardized diagnostic criteria, and most published cases involve eczema rather than psoriasis. Never stop a prescribed topical steroid abruptly — talk to your doctor about a supervised taper.

Does the gut affect psoriasis?

It is an active and promising research area. Studies report that people with psoriasis tend to show reduced gut microbial diversity and lower levels of short-chain-fatty-acid-producing bacteria, and some research links gut barrier markers to psoriasis severity. What has not been established is that any particular supplement changes the course of psoriasis. Kapyderm supplements are food supplements, not a treatment for psoriasis, and diet or supplement changes are worth discussing with your physician.

What does psoriasis look like on darker skin tones?

On skin of color, plaques often appear purple, grayish or dark brown rather than the classic red or pink, and scaling can look ashy. These differences contribute to psoriasis being underdiagnosed in people with darker skin. Post-inflammatory hyperpigmentation — dark marks remaining after plaques clear — is also more pronounced and longer-lasting on melanin-rich skin. Ask a dermatologist who regularly sees your skin tone.

Is the Kapyderm body psoriasis routine different from the scalp one?

Yes, in both formulation and components. The body range is intended for the elbows, knees, lower back and trunk, while the scalp range uses formats suited to hair-bearing skin. Both are cosmetic skin care routines rather than treatments for psoriasis, and both are intended to sit alongside the care a dermatologist provides. See the dedicated scalp psoriasis guide for that range.

Related Resources

01 Find a Certified Kapyderm Specialist near you → 02 Browse the Body Skin Care Range → 03 Scalp Psoriasis — Complete Clinical Guide →

Clinical References & Sources

1. Armstrong AW, et al. Psoriasis. Nature Reviews Disease Primers. 2025. IL-23/Th17 axis; comorbidities; HLA-C*06:02; management. nature.com
2. National Psoriasis Foundation. Psoriasis Statistics and Prevalence of Psoriasis. More than 8 million Americans; 125 million worldwide per the World Psoriasis Day consortium; 80–90% plaque psoriasis; ~30% develop psoriatic arthritis; prevalence by race (Whites 3.6%, Asians 2.5%, Hispanics 1.9%, Blacks 1.5%) with NPF's own note that these may reflect underdiagnosis and disparities in dermatologic care. psoriasis.org/psoriasis-statistics · prevalence page
3. Dermatology Times. 2025 Year in Review: Psoriasis. Treatment landscape overview — a trade publication, not a primary clinical source. dermatologytimes.com
4. Qasem SF, et al. Therapeutic Advancements in the Management of Psoriasis. Cureus. 2025. Medication triggers including lithium, beta-blockers and NSAIDs; corticosteroid tachyphylaxis. PMC11920851
5. JMIR Dermatology. Google Trends in Dermatology: A Scoping Review. Seasonal variation in psoriasis search volume. Search interest is an indirect signal, not a clinical measurement. derma.jmir.org
6. Case report: Iatrogenic Cushing's syndrome induced by topical steroid overuse in a patient with psoriasis. 2025. A single case report — the rarest end of the risk spectrum, included for completeness rather than as a typical outcome. PMC12515825
7. Are there any concerns about the usage of biological agents in psoriasis? Patient hesitancy about biologics; infection risk concerns. PMC11407340
8. Maskey AR, Sasaki A, Sargen M, et al. Breaking the cycle: a comprehensive exploration of topical steroid addiction and withdrawal. Frontiers in Allergy. 2025;6:1547923. doi:10.3389/falgy.2025.1547923. PMID 40230788. PMC11994697
9. Medicines and Healthcare products Regulatory Agency (MHRA). Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions. Drug Safety Update, Volume 17, Issue 10, May 2024. Reactions reported after generally six months or more of moderate or stronger potency use; MHRA also notes no accepted clinical definition. gov.uk/drug-safety-update
10. Topical steroid withdrawal syndrome: clinical cases and a narrative review. Journal of Clinical Medicine. 2026;15(1):361. doi:10.3390/jcm15010361. Published January 3, 2026. 16 patients enrolled in an NIH clinical trial (NCT04864886); describes TSW as underrecognized and at times controversial. mdpi.com
11. Immunoprotective and neuroprotective properties of the gut microbiome in psoriasis. Gut-brain-skin axis; reduced microbial diversity; SCFA-producing bacteria. PMC12816903
12. Frontiers in Microbiology. Psoriasis and gut microbes: research advances from mechanism to therapy. 2025;16:1711288. doi:10.3389/fmicb.2025.1711288. Intestinal barrier markers and psoriasis severity. frontiersin.org

12 sources: 8 peer-reviewed or PubMed-indexed, 1 regulatory (ref. 9, MHRA), 1 patient-advocacy organization (ref. 2, NPF), 1 trade publication (ref. 3), and 1 search-volume review (ref. 5). Ref. 6 is a single case report. No controlled trial of any Kapyderm product in psoriasis exists. Where sources disagree — on US prevalence figures and on the status of TSW as a diagnosis — this article states the disagreement rather than choosing a number. Last reviewed August 2026.

KU

Kapyderm USA

Clinical Education Team

Kapyderm USA distributes professional Dermotricology scalp and skin care formulas made by Laboratorios Kapyderm (Málaga, Spain), and publishes educational material on skin and scalp health. Our articles are educational and are not medical advice. Kapyderm products are cosmetic formulas, not drugs, and are not a treatment for psoriasis or any other medical condition.

Gentle Daily Skin Care.
No Steroids. No Coal Tar.

The Kapyderm body range is a plant-based cosmetic system for daily comfort — softening surface scale, gentle cleansing, and barrier support. EU-regulated and suitable for all skin tones. Made to sit alongside the care your dermatologist provides, not to replace it.

Browse the Range → Find a Certified Specialist →

Questions before you start? Get in touch — or find a certified center.

Continue reading

Scalp Conditions

Scalp Psoriasis — Complete Clinical Guide & Plant-Based Skin Care

Skin Conditions

Eczema & Atopic Dermatitis: Causes, TSW & Care — 2026 Clinical Guide

Skin Conditions

Acne: Causes, Types & What the Antibiotic Resistance Data Shows

Explore Kapyderm USA Browse the Range · Scalp Psoriasis Guide · Eczema Guide · All Articles · Find a Certified Center · Contact →